
A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
Click the title above to open the BioPharm International April 2013 issue in an interactive PDF format.
over 13 years ago
Milestones and Moderate Progress in 2012 Drug Approvalsover 13 years ago
Custom-Cell Products: Diversified In Vitro Modelsover 13 years ago
Benchmarking: Don't Just Run the Numbers, Understand the Processover 13 years ago
Strategic Partnering for Manufacturingover 13 years ago
State of Quality and Compliance in the Biopharmaceutical Industryover 13 years ago
Navigating Emerging Markets — Latin Americaover 13 years ago
Manufacturers Under Pressure to Manage Painkillersover 13 years ago
Prescribing Caution for Biosimilarsover 13 years ago
Financing Innovation





